Suppr超能文献

从化疗到生物疗法:减少全身癌症治疗副作用的新概念综述(综述)。

From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review).

机构信息

Immunological and Oncological Center Cologne (IOZK), D-50674 Cologne, Germany.

出版信息

Int J Oncol. 2019 Feb;54(2):407-419. doi: 10.3892/ijo.2018.4661. Epub 2018 Dec 10.

Abstract

The side effects of systemic chemotherapy used to treat cancer are often severe. For decades, oncologists have focused on treating the tumor, which may result in damage to the tumor‑bearing host and its immune system. Recently, much attention has been paid to the immune system of patients and its activation via biological therapies. Biological therapies, including immunotherapy and oncolytic virus (OV) therapy, are often more physiological and well tolerated. The present review elucidated how these therapies work and why these therapies may be better tolerated: i) In contrast to chemotherapy, immunotherapies induce a memory function of the adaptive immunity system; ii) immunotherapies aim to specifically activate the immune system against cancer; side effects are low due to immune tolerance mechanisms, which maintain the integrity of the body in the presence of B and T lymphocytes with their antigen‑receptor specificities and; iii) the type I interferon response, which is evoked by OVs, is an ancient innate immune defense system. Biological and physiological therapies, which support the immune system, may therefore benefit cancer treatment. The present review focused on immunotherapy, with the aim of reducing side effects and increasing long‑lasting efficacy in cancer therapy.

摘要

用于治疗癌症的全身性化疗的副作用通常很严重。数十年来,肿瘤学家一直专注于治疗肿瘤,这可能导致肿瘤宿主及其免疫系统受损。最近,人们越来越关注患者的免疫系统及其通过生物疗法的激活。生物疗法,包括免疫疗法和溶瘤病毒(OV)疗法,通常更具生理性且耐受性更好。本综述阐明了这些疗法的作用机制以及为何这些疗法可能更耐受:i)与化疗相比,免疫疗法诱导适应性免疫系统的记忆功能;ii)免疫疗法旨在特异性激活免疫系统对抗癌症;由于免疫耐受机制,副作用较低,该机制在存在具有抗原受体特异性的 B 和 T 淋巴细胞时保持身体的完整性;iii)OV 引发的 I 型干扰素反应是一种古老的先天免疫防御系统。因此,支持免疫系统的生物和生理疗法可能有益于癌症治疗。本综述重点介绍了免疫疗法,旨在减少副作用并提高癌症治疗的长期疗效。

相似文献

2
The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
Future Oncol. 2015;11(4):675-89. doi: 10.2217/fon.14.254.
3
Oncolytic viruses and their application to cancer immunotherapy.
Cancer Immunol Res. 2014 Apr;2(4):295-300. doi: 10.1158/2326-6066.CIR-14-0015.
4
Oncolytic viruses: a novel form of immunotherapy.
Expert Rev Anticancer Ther. 2008 Oct;8(10):1581-8. doi: 10.1586/14737140.8.10.1581.
6
Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
BioDrugs. 2019 Oct;33(5):485-501. doi: 10.1007/s40259-019-00367-0.
7
Development of oncolytic virotherapy: from genetic modification to combination therapy.
Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7.
8
Virotherapy: From single agents to combinatorial treatments.
Biochem Pharmacol. 2020 Jul;177:113986. doi: 10.1016/j.bcp.2020.113986. Epub 2020 Apr 21.
9
Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.
Mol Ther. 2018 Jan 3;26(1):56-69. doi: 10.1016/j.ymthe.2017.10.014. Epub 2017 Oct 24.
10
Determinants of the efficacy of viro-immunotherapy: A review.
Cytokine Growth Factor Rev. 2020 Dec;56:124-132. doi: 10.1016/j.cytogfr.2020.07.001. Epub 2020 Sep 6.

引用本文的文献

1
Motivation, barriers, and willingness to participate in clinical trials for novel cancer treatments among the Vietnamese population.
PLoS One. 2025 Aug 29;20(8):e0331250. doi: 10.1371/journal.pone.0331250. eCollection 2025.
2
Apoptosis-Inducing Effects of DS0709 in Colorectal Cancer.
J Microbiol Biotechnol. 2025 Aug 15;35:e2504042. doi: 10.4014/jmb.2504.04042.
4
A bibliometric assessment of research trends and emerging themes at the nexus of chemotherapy and depression.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug 12. doi: 10.1007/s00210-025-04500-5.

本文引用的文献

1
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time.
Front Immunol. 2018 Oct 1;9:2265. doi: 10.3389/fimmu.2018.02265. eCollection 2018.
2
A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
J Autoimmun. 2018 Dec;95:77-99. doi: 10.1016/j.jaut.2018.08.007. Epub 2018 Aug 31.
3
Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2018 Aug;16(8):986-1017. doi: 10.6004/jnccn.2018.0066.
4
Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
Expert Rev Vaccines. 2018 Aug;17(8):697-705. doi: 10.1080/14760584.2018.1506332. Epub 2018 Aug 22.
5
Recurrent Glioblastoma Treated with Recombinant Poliovirus.
N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26.
6
Oncolytic Virotherapy by HSV.
Adv Exp Med Biol. 2018;1045:63-84. doi: 10.1007/978-981-10-7230-7_4.
7
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.
Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10.
8
Integrating oncolytic viruses in combination cancer immunotherapy.
Nat Rev Immunol. 2018 Aug;18(8):498-513. doi: 10.1038/s41577-018-0014-6.
9
Imaging of cytotoxic antiviral immunity while considering the 3R principle of animal research.
J Mol Med (Berl). 2018 Apr;96(3-4):349-360. doi: 10.1007/s00109-018-1628-7. Epub 2018 Feb 19.
10
Origin and differentiation of human memory CD8 T cells after vaccination.
Nature. 2017 Dec 21;552(7685):362-367. doi: 10.1038/nature24633. Epub 2017 Dec 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验